Clinical Trial Results:
A multicentre, randomised, double-blind, placebo-controlled trial of a novel CCR5 antagonist, UK-427,857 in combination with optimised background therapy versus optimised background therapy alone for the treatment of antiretroviral-experienced HIV-1 infected subjects.
Summary
|
|
EudraCT number |
2004-001778-21 |
Trial protocol |
SE DE ES IT GB |
Global completion date |
19 Apr 2011
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
15 Jul 2016
|
First version publication date |
15 Jul 2016
|
Other versions |
|
Summary report(s) |
A4001028 Public Disclosure Synopsis |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.